Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous: 20 mg/5 mL (4 mg/mL)) |
| Drug Class | CC chemokine receptor type 4 (CCR4)- directed monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
Summary
- Mogamulizumab-kpkc (Poteligeo) is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
- Four systematic reviews/meta-analyses were reviewed to gather information about this drug and its effectiveness in treating these conditions.
- The National Institute for Health and Care Excellence (NICE) found that mogamulizumab-kpkc showed favorable results in patients with mycosis fungoides and Sézary syndrome, but there was uncertainty due to study design, specifically crossover of patients from a trial called MAVORIC which compared mogamulizumab to vorinostat, not standard care in the NHS.
- A review examining survival outcomes for Adult T-cell leukemia-lymphoma treated with various therapies found that mogamulizumab was frequently studied and potentially provided longer survival compared to chemotherapy alone; however, future comparisons are needed for clearer insights into treatment efficacy.
- Another review evaluating safety profile of mogamulizumab concluded it had clinically meaningful antitumor activity with acceptable toxicity when used as monotherapy or combined therapy; common adverse events included lymphopenia, infusion reaction fever rash chills neutropenia anaemia gastrointestinal disorder among others depending on whether it's used alone or combined respectively.
- In a prospective cohort study conducted at Zagazig University Hospital Egypt between 2017-2022 involving 64 classical Hodgkin lymphoma (CHL) patients divided into EBV-positive & EBV-negative groups,it was observed that EBV-positive CHL patients who expressed mRNAs molecules & end product proteins associated with JAK/STAT & NF-KB pathways were more susceptible to cancer progression.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Poteligeo (mogamulizumab-kpkc) Prescribing Information. | 2022 | Kyowa Kirin, Inc., Bedminster, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. | 2020 | Journal for ImmunoTherapy of Cancer |